Elizabeth O’Farrell was appointed to the board of SpyGlass Pharma, which is led by CEO Patrick Mooney. Elizabeth previously gained experience at Eli Lilly.
Steady: 0 in the last 7 days
Updated oct 19
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Elizabeth O’Farrell was appointed to the board of SpyGlass Pharma, which is led by CEO Patrick Mooney. Elizabeth previously gained experience at Eli Lilly.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Patrick Mooney's company has developed a treatment for OHT, with clinical development being overseen.Sub-event
Elizabeth O’Farrell joins SpyGlass Pharma board; CEO Patrick Mooney leads; Elizabeth previously worked at Eli Lilly.1 source
Keep exploring
The entities involved
-
Elizabeth
Nothing else this week.
-
Spyglass
company
Nothing else this week.
-
Patrick Mooney
researcher
Nothing else this week.
-
Eli Lilly and Company
American pharmaceutical company
- Global market sentiment is being influenced by geopolitical conflict in the Middle East, impacting the competitive landscape of diabetes and obesity drug companies like Novo Nordisk and Eli Lilly.
- FDA approved Rasonque for pancreatic cancer, while Revolution Medicines evaluates therapy with Merck's Keytruda and compares its market cap to Eli Lilly.
Coverage
Newest first; wire copies grouped- GlobeNewswireSpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, toda